Members

Marcus Hompesch, MD, is Chief Executive Officer and Chairman of the Board of ProSciento and has led the clinical research organization (CRO), exclusively focused on NASH, diabetes and obesity, since its inception in 2003. He is also editor-in-chief of the journal Endocrinology, Diabetes & Metabolism, a Wiley publication. His career and track record in metabolism-focused clinical R&D, spanning more than 25 years in academic and industry settings, includes contributions to clinical development strategies and early phase clinical research studies for many of the diabetes and related metabolic drugs and devices on the market globally.

Dr. Hompesch is an author of more than 100 publications, including peer-reviewed journals and editorials and is a regular peer reviewer for scientific journals relevant to metabolic diseases. He is also an editor and co-author of the textbooks Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development (1st Ed. 2015) and Translational Research Methods in Diabetes, Obesity, and Nonalcoholic Fatty Liver Disease: A Focus on Early Phase Clinical Drug Development (2nd Ed. 2019).